Literature DB >> 18372355

Lupus: improving long-term prognosis.

A Doria1, C Briani.   

Abstract

Over recent decades short- and medium-term survival has greatly improved in patients affected with systemic lupus erythematosus, but long-term prognosis still remains poor mainly due to complications of the disease and/or its treatment. To improve long-term prognosis in systemic lupus erythematosus, we should try to adopt, early in the disease course, strategies that can contribute to reducing long-term complications, including screening for and prophylaxis against infections, control of risk factors for atherosclerosis, and cancer surveillance. However, in patients with systemic lupus erythematosus all these preventive strategies are often not sufficient. Indeed, two important systemic lupus erythematosus-related factors play a relevant role in all these complications: severe disease manifestations, such as glomerulonephritis and central nervous system involvement, and corticosteroid and cyclophosphamide use. Therefore, to prevent long-term complications, we should try to control disease activity and severity using the lowest effective dosage of these drugs. Moreover, strategies directed at preventing clinical manifestations in asymptomatic antinuclear antibody-positive individuals or in antiphospholipid antibody-positive systemic lupus erythematosus patients, as well as at preventing severe manifestations in patients with mild systemic lupus erythematosus at the time of the diagnosis should be considered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18372355     DOI: 10.1177/0961203307087612

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  11 in total

Review 1.  Current and novel therapeutics in the treatment of systemic lupus erythematosus.

Authors:  Cagri Yildirim-Toruner; Betty Diamond
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

2.  Assessment of a high-avidity IgG ANAs for the diagnosis and activity prediction of systemic lupus erythematosus.

Authors:  Yanli Zeng; Yiqiang Lin; Xuelian Wang; Yan Zhang; Feng Peng; JiaJia Wang; Longcan Jiang; Shiqiong Liang; Yun Xiao
Journal:  Clin Rheumatol       Date:  2020-03-18       Impact factor: 2.980

3.  Cricoarytenoiditis as an initial manifestation of systemic lupus erythematosus.

Authors:  Jean-Michel Hougardy; Nicolas Roper; Alain Michils; Muhammad S Soyfoo
Journal:  Case Rep Rheumatol       Date:  2011-09-07

Review 4.  Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy.

Authors:  Toshiharu Hayashi
Journal:  J Biomed Biotechnol       Date:  2010-08-17

5.  Human papillomavirus vaccine and systemic lupus erythematosus.

Authors:  Mariele Gatto; Nancy Agmon-Levin; Alessandra Soriano; Raffaele Manna; Ramit Maoz-Segal; Shaye Kivity; Andrea Doria; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2013-04-28       Impact factor: 3.650

6.  Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.

Authors:  Michael F Loncharich; Caleb W Anderson
Journal:  ACR Open Rheumatol       Date:  2022-02-14

Review 7.  Protective molecules and their cognate antibodies: new players in autoimmunity.

Authors:  Margherita Zen; Nicola Bassi; Carla Campana; Silvano Bettio; Elena Tarricone; Linda Nalotto; Anna Ghirardello; Andrea Doria
Journal:  Auto Immun Highlights       Date:  2010-11-04

8.  Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.

Authors:  Richard Furie; Munther Khamashta; Joan T Merrill; Victoria P Werth; Kenneth Kalunian; Philip Brohawn; Gabor G Illei; Jorn Drappa; Liangwei Wang; Stephen Yoo
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

9.  Drug utilization and therapy provision patterns by prescriber types among patients with systemic lupus erythematosus in Korea.

Authors:  Sooyoung Shin
Journal:  Patient Prefer Adherence       Date:  2017-10-17       Impact factor: 2.711

10.  Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.

Authors:  Munther Khamashta; Joan T Merrill; Victoria P Werth; Richard Furie; Kenneth Kalunian; Gabor G Illei; Jorn Drappa; Liangwei Wang; Warren Greth
Journal:  Ann Rheum Dis       Date:  2016-03-23       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.